A citation-based method for searching scientific literature

Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm, Jeffrey L Probstfield, Denise G Simons-Morton, William T Friedewald. N Engl J Med 2008
Times Cited: 5002







List of co-cited articles
439 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
81
2

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
225
2

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
T Nishikawa, D Edelstein, X L Du, S Yamagishi, T Matsumura, Y Kaneda, M A Yorek, D Beebe, P J Oates, H P Hammes,[...]. Nature 2000
2


Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.
John W McEvoy, Yuan Chen, Andreea Rawlings, Ron C Hoogeveen, Christie M Ballantyne, Roger S Blumenthal, Josef Coresh, Elizabeth Selvin. J Am Coll Cardiol 2016
167
2

Exercise treadmill score for predicting prognosis in coronary artery disease.
D B Mark, M A Hlatky, F E Harrell, K L Lee, R M Califf, D B Pryor. Ann Intern Med 1987
427
2

Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease.
D B Mark, L Shaw, F E Harrell, M A Hlatky, K L Lee, J R Bengtson, C B McCants, R M Califf, D B Pryor. N Engl J Med 1991
550
2

Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound.
Alexander W Leber, Andreas Knez, Franz von Ziegler, Alexander Becker, Konstantin Nikolaou, Stephan Paul, Bernd Wintersperger, Maximilian Reiser, Christoph R Becker, Gerhard Steinbeck,[...]. J Am Coll Cardiol 2005
894
2


Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Tina Ken Schramm, Gunnar H Gislason, Lars Køber, Søren Rasmussen, Jeppe N Rasmussen, Steen Z Abildstrøm, Morten Lock Hansen, Fredrik Folke, Pernille Buch, Mette Madsen,[...]. Circulation 2008
357
2

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
Alan S Go, Glenn M Chertow, Dongjie Fan, Charles E McCulloch, Chi-yuan Hsu. N Engl J Med 2004
2

Metformin: historical overview.
Clifford J Bailey. Diabetologia 2017
228
2

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis,[...]. Lancet Diabetes Endocrinol 2017
274
2

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
David J Graham, Rita Ouellet-Hellstrom, Thomas E MaCurdy, Farzana Ali, Christopher Sholley, Christopher Worrall, Jeffrey A Kelman. JAMA 2010
363
2

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Adriaan Kooy, Jolien de Jager, Philippe Lehert, Daniël Bets, Michiel G Wulffelé, Ab J M Donker, Coen D A Stehouwer. Arch Intern Med 2009
246
2

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun. Sci Rep 2017
83
2

Metformin use and mortality among patients with diabetes and atherothrombosis.
Ronan Roussel, Florence Travert, Blandine Pasquet, Peter W F Wilson, Sidney C Smith, Shinya Goto, Philippe Ravaud, Michel Marre, Avi Porath, Deepak L Bhatt,[...]. Arch Intern Med 2010
241
2

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman,[...]. Cardiovasc Diabetol 2014
128
2

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Soffia Gudbjörnsdottir. N Engl J Med 2017
29
6


Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS).
Sabita S Soedamah-Muthu, Nish Chaturvedi, Daniel R Witte, Lynda K Stevens, Massimo Porta, John H Fuller. Diabetes Care 2008
155
2

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen,[...]. Eur J Heart Fail 2017
185
2

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J Tuomilehto, J Lindström, J G Eriksson, T T Valle, H Hämäläinen, P Ilanne-Parikka, S Keinänen-Kiukaanniemi, M Laakso, A Louheranta, M Rastas,[...]. N Engl J Med 2001
2

GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Miriam Longo, Paolo Chiodini, Katherine Esposito. Diabetes Obes Metab 2019
61
3

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann,[...]. Eur J Heart Fail 2019
108
2

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Kenneth B Margulies, Adrian F Hernandez, Margaret M Redfield, Michael M Givertz, Guilherme H Oliveira, Robert Cole, Douglas L Mann, David J Whellan, Michael S Kiernan, G Michael Felker,[...]. JAMA 2016
273
2

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, Paula S Curtis, Ramon Gomis, Markolf Hanefeld, Nigel P Jones, Michel Komajda, John J V McMurray. Lancet 2009
924
2

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
K Malmberg, L Rydén, H Wedel, K Birkeland, A Bootsma, K Dickstein, S Efendic, M Fisher, A Hamsten, J Herlitz,[...]. Eur Heart J 2005
703
2

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
Deepak L Bhatt, P Gabriel Steg, E Magnus Ohman, Alan T Hirsch, Yasuo Ikeda, Jean-Louis Mas, Shinya Goto, Chiau-Suong Liau, Alain J Richard, Joachim Röther,[...]. JAMA 2006
2

Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis.
Diewertje Sluik, Brian Buijsse, Rebecca Muckelbauer, Rudolf Kaaks, Birgit Teucher, Nina Føns Johnsen, Anne Tjønneland, Kim Overvad, Jane Nautrup Ostergaard, Pilar Amiano,[...]. Arch Intern Med 2012
120
2


Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.
C Andersson, L van Gaal, I D Caterson, P Weeke, W P T James, W Coutinho, N Finer, A M Sharma, A P Maggioni, C Torp-Pedersen. Diabetologia 2012
47
4

Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study.
Angus Forbes, Trevor Murrells, Henrietta Mulnier, Alan J Sinclair. Lancet Diabetes Endocrinol 2018
71
2

HbA1C variability and the risk of renal status progression in Diabetes Mellitus: a meta-analysis.
Dongsheng Cheng, Yang Fei, Yumei Liu, Junhui Li, Qin Xue, Xiaoxia Wang, Niansong Wang. PLoS One 2014
28
7

Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Chengsheng Ju, Rachel Wing Chuen Lai, Ka Hou Christien Li, Joshua Kai Fung Hung, Jenny C L Lai, Jeffery Ho, Yingzhi Liu, Man Fung Tsoi, Tong Liu, Bernard Man Yung Cheung,[...]. Rheumatology (Oxford) 2020
15
13

Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus.
Jun Gu, Jian-An Pan, Yu-Qi Fan, Hui-Li Zhang, Jun-Feng Zhang, Chang-Qian Wang. Cardiovasc Diabetol 2018
25
8

Molecular and Electrophysiological Mechanisms Underlying Cardiac Arrhythmogenesis in Diabetes Mellitus.
Gary Tse, Eric Tsz Him Lai, Vivian Tse, Jie Ming Yeo. J Diabetes Res 2016
54
3

Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry.
Andrea O Y Luk, Ronald C W Ma, Eric S H Lau, Xilin Yang, Winnie W Y Lau, Linda W L Yu, Francis C C Chow, Juliana C N Chan, Wing-Yee So. Diabetes Metab Res Rev 2013
81
2



A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.
Johan Wadén, Carol Forsblom, Lena M Thorn, Daniel Gordin, Markku Saraheimo, Per-Henrik Groop. Diabetes 2009
142
2


Vascular disease and diabetes: is hypoglycaemia an aggravating factor?
Rohana J Wright, Brian M Frier. Diabetes Metab Res Rev 2008
209
2

The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
James M Hempe, Shuqian Liu, Leann Myers, Robert J McCarter, John B Buse, Vivian Fonseca. Diabetes Care 2015
87
2

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
108
2

Stroke recurrence within 2 years after ischemic infarction.
D B Hier, M A Foulkes, M Swiontoniowski, R L Sacco, P B Gorelick, J P Mohr, T R Price, P A Wolf. Stroke 1991
213
2

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Kenneth W Mahaffey, Gail Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow,[...]. Am Heart J 2013
116
2

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
Martin J O'Donnell, Denis Xavier, Lisheng Liu, Hongye Zhang, Siu Lim Chin, Purnima Rao-Melacini, Sumathy Rangarajan, Shofiqul Islam, Prem Pais, Matthew J McQueen,[...]. Lancet 2010
2

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig, Gregory P Samsa, Irfan Altafullah, Lucy Y Ledbetter, Mary J MacLeod, Russell Scott,[...]. Arch Neurol 2011
65
3

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T George,[...]. Circulation 2019
85
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.